Benzoic acid,2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,hydrochloride (1:1) cas no:36508-71-1
Synonyms: Benzoicacid, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,monohydrochloride (9CI); Benzoic acid, [1-[4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,monohydrochloride, (2S-cis)-; NSC 164011; RP 22050 hydrochloride; Rubidazonehydrochloride; Zorubicin hydrochloride
NameBenzoic acid,2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,hydrochloride (1:1)
CAS36508-71-1
SynonymsBenzoicacid, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,monohydrochloride (9CI); Benzoic acid, [1-[4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide,monohydrochloride, (2S-cis)-; NSC 164011; RP 22050 hydrochloride; Rubidazonehydrochloride; Zorubicin hydrochloride
EINECS(EC#)253-076-4
Molecular FormulaC34H35 N3 O10 . Cl H
Molecular Weight682.12
refractive index1.705
Safety
Poison by intraperitoneal route. Human systemic effects by intravenous route: cardiovascular, blood, and gastrointestinal system effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and HCl. Used as an antineoplastic agent. See also RUBIDAZONE.
| 1. |
|
mmo-sat 20 µg/plate
|
|
EJCAAH European Journal of Cancer. 19 (1983),641. |
| 2. |
|
mma-sat 4 µg/plate
|
|
EJCAAH European Journal of Cancer. 19 (1983),641. |
| 3. |
|
pic-esc 700 µg/L
|
|
MUREAV Mutation Research. 77 (1980),197. |
| 4. |
|
oms-hmn:lym 1 mg/L
|
|
EJCAAH European Journal of Cancer. 14 (1978),741. |
| 5. |
|
ivn-hmn TDLo:48 mg/kg/21D-I:CVS,GIT,BLD
|
|
CTRRDO Cancer Treatment Reports. 62 (1978),1053. |
| 6. |
|
ipr-mus LD50:28,710 µg/kg
|
|
NCISP* National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program, Bethesda, MD 20205 JAN86 . |
